Indeed, NRF2 was considered a negative regulator of ferroptosis since inhibition of this gene sensitizes head and neck cancer cells to ferroptosis and its high expression promotes resistance in glioma cells [21–23]. The gene discussed is NFE2L2; the disease is central nervous system cancer.